Trial Profile

A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

01 Jun 2019 Trial has been discontinued in UK.
14 Dec 2015 Results of retrospective analysis of COMPARZ study as well as pooled data from phase II (VEG102616) and phase III (VEG105192) studies of pazopanib have been published in the European Journal of Cancer
02 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com